Abstract
In this chapter, next-generation sequencing of the entire viral genome of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is described. Successful sequencing of the SARS-CoV-2 virus is dependent upon quality of the specimen, adequate coverage of the entire genome, and up-to-date annotation. Some of the advantages of performing SARS-CoV-2 surveillance using next-generation sequencing are scalability, high-throughput, cost, and full genome analysis. Some of the disadvantages can be expensive instrumentation, large upfront reagent and supply costs, increased time-to-result, computational needs, and complicated bioinformatics. This chapter will provide an overview of a modified FDA Emergency Use Authorization procedure for the genomic sequencing of SARS-CoV-2. The procedure is also referred to as the research use only (RUO) version.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
World Health Organization (2020) Coronavirus disease (COVID-19): virus evolution. https://www.who.int/news-room/questions-and-answers/item/sars-cov-2-evolution. Accessed July 7, 2022
Center for Disease Control and Prevention (2022) SARS-CoV-2 variant classifications and definitions. https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-classifications.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Fvariants%2Fvariant-info.html. Accessed July 7, 2022
Protocols.io (2020) nCoV-2019 sequencing protocol v3 (LoCost) V.3. https://www.protocols.io/view/ncov-2019-sequencing-protocol-v3-locost-bh42j8ye?version_warning=no. Accessed July 7, 2022
Charre C, Ginevra C, Sabatier M, Regue H, Destras G, Brun S et al (2020) Evaluation of NGS-based approaches for SARS-CoV-2 whole genome characterisation. Virus Evol 6(2):veaa075. https://doi.org/10.1093/ve/veaa075. Accessed July 7, 2022
Febbo P (2020) How sequencing-based surveillance helps fight COVID-19. https://www.illumina.com/company/news-center/blog/sequencing-based-surveillance-helps-fight-covid-19.html. Accessed July 7, 2022
Illumina Inc. (2022) COVIDSeq test (RUO Version). https://www.illumina.com/products/by-type/clinical-research-products/covidseq.html. Accessed July 7, 2022
Artic Network (2022) Artic Network covid sequencing protocol. https://artic.network/ncov-2019. Accessed July 7, 2022
Illumina Inc. (2022) Illumina COVIDSeq test. https://www.illumina.com/products/by-type/ivd-products/covidseq.html. Accessed July 7, 2022
Acknowledgments
This work was supported by the South Carolina Cares Act 2020 and 2021.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2023 The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Hirschhorn, J.W., Dunne, J. (2023). SARS-CoV-2 Sequencing for Variant Surveillance. In: Myers, M.B., Schandl, C.A. (eds) Clinical Applications of Nucleic Acid Amplification. Methods in Molecular Biology, vol 2621. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-2950-5_16
Download citation
DOI: https://doi.org/10.1007/978-1-0716-2950-5_16
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-0716-2949-9
Online ISBN: 978-1-0716-2950-5
eBook Packages: Springer Protocols